Predicted to enable high-density lipoprotein particle binding activity and mRNA base-pairing translational repressor activity. Predicted to be involved in several processes, including miRNA-mediated post-transcriptional gene silencing; negative regulation of G1/S transition of mitotic cell cycle; and negative regulation of canonical NF-kappaB signal transduction. Predicted to act upstream of or within several processes, including cellular response to forskolin; long-term synaptic potentiation; and negative regulation of osteoblast differentiation. Predicted to be located in extracellular exosome. Predicted to be part of RISC complex. Orthologous to human MIR30C2 (microRNA 30c-2); INTERACTS WITH bleomycin A2; nitrofen; paracetamol.
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR30C2 mRNA
[Plant Extracts co-treated with Resveratrol] results in decreased expression of MIR30C2 mRNA and [Plant Extracts co-treated with Resveratrol] results in increased expression of MIR30C2 mRNA
Carbon Tetrachloride results in decreased expression of MIR30C2 mRNA and Carbon Tetrachloride results in decreased expression of MIR30C2 mRNA alternative form
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR30C2 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR30C2 mRNA
[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MIR30C2 mRNA